Aclidinium bromide

Aclidinium bromide

Systematic (IUPAC) name
[(8R)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octan-8-yl] 2-hydroxy-2,2-dithiophen-2-ylacetate bromide
Clinical data
Trade names	Bretaris Genuair, Eklira Genuair, Tudorza Pressair
Licence data	US FDA:link
Pregnancy category	US: C (Risk not ruled out)
Legal status	US: ℞-only
Routes of administration	Inhalational
Identifiers
CAS Number	320345-99-1
ATC code	R03BB05
PubChem	CID 11519741
ChemSpider	9694529
UNII	UQW7UF9N91
KEGG	D08837
ChEBI	CHEBI:65344
ChEMBL	CHEMBL551466
Chemical data
Formula	C26H30BrNO4S2
Molar mass	564.55 g·mol^−1
SMILES [Br-].O=C(O[C@@H]3C2CC[N+](CCCOc1ccccc1)(CC2)C3)C(O)(c4sccc4)c5sccc5
InChI InChI=1S/C26H30NO4S2.BrH/c28-25(26(29,23-9-4-17-32-23)24-10-5-18-33-24)31-22-19-27(14-11-20(22)12-15-27)13-6-16-30-21-7-2-1-3-8-21;/h1-5,7-10,17-18,20,22,29H,6,11-16,19H2;1H/q+1;/p-1/t20?,22-,27?;/m0./s1 Key:XLAKJQPTOJHYDR-QTQXQZBYSA-M
(what is this?)  (verify)

Aclidinium bromide (INN) is a long-acting, inhaled muscarinic antagonist approved in the US on July 24, 2012^[1] as a maintenance treatment for chronic obstructive pulmonary disease (COPD).^[2]

Evidence shows that it can improve quality of life and prevent hospitalization in those with COPD.^[3] However, it does not appear to affect the risk of death or the frequency steroids are needed.^[3] It is unclear if it differs from the similar medication tiotropium or another commonly used medication class of LAMAs.^[3]

Aclidinium is delivered via a multidose dry powder inhaler, the Genuair inhaler.

Brand names

It is marketed under the brand name Tudorza Pressair in the US, Eklira Genuair in the UK, and Tudorza Genuair in Canada; licensed to Menarini under the brand name Bretaris Genuair for majority of EU member states^[4]

References

1. "Forest Laboratories and Almirall Announce FDA Approval of Tudorza™ Pressair™ for the Long-Term Maintenance Treatment of COPD" (Press release). Forest Laboratories. Retrieved 2012-07-24.
2. Gavaldà A, Miralpeix M, Ramos I; et al. (2009). "Characterization of aclidinium bromide, a novel inhaled muscarinic antagonist, with long duration of action and a favorable pharmacological profile". J Pharmacol Exp Ther.
3. Ni, H; Soe, Z; Moe, S (Sep 19, 2014). "Aclidinium bromide for stable chronic obstructive pulmonary disease.". The Cochrane database of systematic reviews 9: CD010509. doi:10.1002/14651858.CD010509.pub2. PMID 25234126.
4. "Almirall and Menarini sign a licence agreement and commercial alliance for Aclidinium in the majority of European member states and a number of non-EU countries" (Press release). Menarini. Retrieved 2012-03-26.